Advanced Solid Tumors — Expanded Access Programs
Overview
Right2Hope maintains a directory of 46 expanded access programs, clinical trials, and compassionate use pathways listed for Advanced Solid Tumors. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with advanced solid tumors programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 23 programs are currently active or recruiting, with the remaining 23 in other lifecycle stages. Sponsors actively running programs in this area include Bristol-Myers Squibb, Eikon Therapeutics, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Revolution Medicines, Inc., and others.
By recruiting status
Snapshot of where every Advanced Solid Tumors program currently sits in its lifecycle.
- Active / Recruiting23
- Inactive23
Top sponsors
Organisations running the most Advanced Solid Tumors programs in the directory.
- Bristol-Myers Squibb3 programs
- Eikon Therapeutics2 programs
- Merck Sharp & Dohme LLC2 programs
- Regeneron Pharmaceuticals2 programs
- Revolution Medicines, Inc.2 programs
- Abion Inc1 program
- American Society of Clinical Oncology1 program
- Amgen1 program
- AskGene Pharma, Inc.1 program
- Astellas Pharma Global Development, Inc.1 program
Advanced Solid Tumors programs (46)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on the Safety and Effectiveness of REGN10597 for Adults with Advanced Solid Tumors — Regeneron Pharmaceuticals
- First-in-Human Study of CKD-703 for Advanced Solid Tumors and Non-Small Cell Lung Cancer — Chong Kun Dang Pharmaceutical
- Phase 1 Study of ZN-A-1041 for HER2-Positive Advanced Solid Tumors — Hoffmann-La Roche
- Study on CS2009 for Adults with Advanced Solid Tumors — CStone Pharmaceuticals
- Study on Continuing Sotorasib Treatment With or Without Panitumumab for Patients With KRAS p.G12C Mutation — Amgen
- Study on FGFR2/3 Inhibitor (CGT4859) for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors — Cogent Biosciences, Inc.
- Study on ASKG915 for Patients with Certain Advanced Solid Tumors — AskGene Pharma, Inc.
- Study on BMS-986482 Alone or in Combination for Advanced Solid Tumors — Bristol-Myers Squibb
- Study on BMS-986490 With or Without Bevacizumab for Advanced Solid Tumors — Bristol-Myers Squibb
- Study on Durvalumab and Monalizumab for Treating Advanced Solid Tumors — MedImmune LLC
- Study on MRG002 for Patients with HER2-Positive Advanced Solid Tumors and Advanced Gastric or Gastroesophageal Cancer — Shanghai Miracogen Inc.
- Study on EIK1004 (IMP1707) for Treating Advanced Solid Tumors — Eikon Therapeutics
- Study on INCB177054 for Patients with Advanced or Metastatic Solid Tumors — Incyte Corporation
- Study on the Safety and Effectiveness of MK-3120 for Treating Advanced Solid Tumors — Merck Sharp & Dohme LLC
- Study on the Safety and Effects of ALK201 in Adults with Advanced Solid Tumors — Shanghai Allink Biotherapeutics Co., Ltd.
- Study on the Effectiveness and Safety of BAY2927088 Tablets for Treating Solid Tumors with HER2 Mutations — Bayer
- Study on JAB-23E73 for Adults with Advanced Solid Tumors with KRAS Alteration — Jacobio Pharmaceuticals Co., Ltd.
- Study on ETX-636 for Adults with Advanced Solid Tumors — Ensem Therapeutics
- Study on the Safety and Effects of WEF-001 for Advanced KRAS-Mutant Solid Tumors — Auricula Biosciences Inc.
- Study on SNV4818 for Adults with Advanced Solid Tumors — Pikavation Therapeutics, Inc.
- Study on DT-7012 Alone and with an Immune Checkpoint Inhibitor for Advanced Solid Tumors — Domain Therapeutics Australia Pty Ltd
- Study on RAS(ON) Inhibitors with Ivonescimab for Patients with Solid Tumors — Revolution Medicines, Inc.
- Study on RMC-6236 for Patients with Advanced Solid Tumors with Specific RAS Mutations — Revolution Medicines, Inc.
- Study on BLU-222 for Advanced Solid Tumors — Blueprint Medicines Corporation
- Study on Sacituzumab Govitecan and Berzosertib for Small Cell Lung Cancer and Other Resistant Cancers — National Cancer Institute (NCI)
- Study on the Safety and Effects of PT-112 Injection for Advanced Solid Tumors — Promontory Therapeutics Inc.
- Study on STAR0602 for Treating Advanced Solid Tumors — Marengo Therapeutics, Inc.
- Study of ASP1570 Alone or with Pembrolizumab in Adults with Solid Tumors — Astellas Pharma Global Development, Inc.
- Study on BMS-986449 With and Without Nivolumab for Advanced Solid Tumors — Bristol-Myers Squibb
- A Study of DB-1311 in Advanced/Metastatic Solid Tumors — DualityBio Inc.
- Study on ICP-192 for Patients with Advanced Solid Tumors — Beijing InnoCare Pharma Tech Co., Ltd.
- Study on OTP-01, a New Treatment for Advanced Solid Tumors — Ottimo Pharma Limited
- Study on the Safety and Effects of NTS071 in Patients with Advanced Solid Tumors with a Specific TP53 Mutation — Nutshell Therapeutics (Shanghai) Co., LTD.
- Study on TROP2 ADC LCB84 Alone and with Anti-PD-1 Antibody for Advanced Solid Tumors — LigaChem Biosciences, Inc.
- A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS — Jiangsu HengRui Medicine Co., Ltd.
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers — Regeneron Pharmaceuticals
- Study on EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors, Including MSI-H Tumors — Eikon Therapeutics
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- First Human Study of TUB-030 for Patients with Advanced Solid Tumors — Tubulis GmbH
- Study on Lurbinectedin and Irinotecan for Patients with Certain Advanced Cancers — PharmaMar
- Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors — TransThera Sciences (Nanjing), Inc.
- Study on mRNA-4359 Alone and with Immune Checkpoint Blockade for Advanced Solid Tumors — ModernaTX, Inc.
- Study of Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors — Merck Sharp & Dohme LLC
- Study to Evaluate CCS1477 in Advanced Tumors — CellCentric Ltd.
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer — American Society of Clinical Oncology
- To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation — Abion Inc
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Advanced Solid Tumors to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.